Synthetic Biology & Genetic Engineering

Leduc used the phrase in Théorie physico-chimique de la vie et générations spontanées, and again in La Biologie Synthétique in 1912. This gave the field its eventual name decades before the molecular tools to realise it existed.

The Canadian-American scientist's demonstration established DNA as the hereditary molecule. It became the bedrock on which all subsequent genetic research, and later synthetic biology, was built.

The double-helix structure revealed how genetic information is encoded and copied. It made rational manipulation of genetic sequence conceivable.

Their study of the lac operon in E. coli established that bacteria switch genes on and off in response to their environment through molecular circuitry, giving biology its first account of genetic regulatory logic. They explicitly envisioned assembling new systems from molecular components, anticipating the engineering logic later synthetic circuits such as the repressilator were built to exploit.

The P.N.A.S. paper demonstrated that DNA could be recombined and propagated in a host organism. It is widely regarded as the dawn of synthetic biology.

The Indian-born biochemist's team built a yeast transfer RNA gene from individual chemical building blocks and showed it worked once inserted into bacteria, establishing that genes could be constructed rather than only extracted from existing organisms.

Restriction nucleases permitted easy construction of recombinant DNA molecules and analysis of individual genes. Szybalski's editorial in Gene marked the arrival of a 'new era of synthetic biology' in which new gene arrangements could be constructed and evaluated.

The Science paper removed the need to add fresh polymerase after each cycle of the polymerase chain reaction. This greatly simplified DNA mutagenesis and assembly, making routine construction of designed sequences practical.

His paper set out the deliberate redesign of an organism's metabolic pathways using recombinant DNA methods as a systematic engineering discipline rather than ad hoc genetic modification, a framing that underpins the industrial strain design synthetic biology later built on.

The repressilator and the genetic toggle switch wired existing genes into bacteria to oscillate or flip between states like simple electronic circuits, demonstrating that genetic regulation could be engineered predictably and marking most historians' starting point for synthetic biology as a field.

The genome was assembled from chemically synthesised 60 to 80-mers. It was an early demonstration that whole viral genomes could be built from scratch.

The two-year effort produced the second synthetic genome, built purely from sequence data. It sharpened both the technical ambition and the biosecurity anxieties of the field.

Using computational modelling rather than modifying an existing natural protein, the team designed an entirely new protein fold from scratch and had it made and shown to fold as predicted, a foundational result for the later field of de novo protein design.

The 5386 bp genome was built far faster than the poliovirus effort. The speed increase signalled that genome synthesis was becoming a routine engineering operation.

BioBrick plasmids became the most widely used standardised DNA parts, enabling modular assembly of genetic constructs. They became central to the iGEM competition founded at MIT the following year.

The work showed that a multi-step natural product pathway could be transplanted into a microbial chassis. It became the flagship demonstration of synthetic biology for pharmaceutical manufacture.

Growing out of an MIT course, the annual competition let student teams worldwide assemble interchangeable genetic parts into working biological systems, spreading engineering-style design principles and training a generation of synthetic biologists internationally.

SB1.0 gathered the emerging community and gave synthetic biology a formal disciplinary identity. The iGEM competition was founded at MIT in the same period.

One group developed bacterial light sensing while another designed circuits capable of multicellular pattern formation. These showed that engineered genetic circuits could process environmental inputs and coordinate across cells.

Inserting genes from wormwood plants and other organisms into brewer's yeast let microbes manufacture artemisinic acid through fermentation, a process Sanofi later scaled to commercial production, becoming synthetic biology's most cited real-world humanitarian success story.

The circuit directed engineered bacteria towards cancer cells. It was an early proof of concept for therapeutic applications of designed genetic systems.

Several companies were reported to be selling made-to-order genetic sequences with turnaround times under two weeks. Commercial availability of cheap DNA synthesis removed a key bottleneck for designers.

The work extended engineered genetic computation from bacteria to human cells. It later underpinned therapeutic biological computation.

A group led by scientists from the major synthesis firms proposed practical self-governance for screening orders. A separate paper the same year identified key issues in safety, security, ethics and the science-society interface.

The July 2009 symposium addressed opportunities and challenges facing the discipline in the United States. It was part of an emerging governance conversation around the field.

The 38-minute film was made to communicate the field and its ramifications to a broader public. It formed part of European efforts to build public dialogue around the technology.

Researchers synthesised the genome of Mycoplasma mycoides, JCVI-syn1.0, from digital DNA sequence data, assembling chemically synthesised fragments by yeast recombination and transplanting the result into a genomically emptied cell of a related species, which then began replicating under the synthetic genome's control. Widely described as creating the first synthetic life, it was the field's landmark demonstration that an entire functioning genome could be built to design.

The commission judged Venter's synthetic genome a significant technical advance but not the creation of life. The report shaped the American regulatory and ethical framing of the field.

The work extended genome synthesis from bacteria into a eukaryotic organism. It laid groundwork for the wider synthetic yeast genome effort.

Continued investment through national research agencies supported automated strain-engineering facilities intended to help local biotech firms design and test engineered organisms faster, part of a wider push to establish Singapore as a synthetic biology hub for the region.

Guidance issued to help national authorities and research institutions assess and manage the risks of life sciences research that could be misused gained further uptake, though implementation remained uneven across countries with limited biosafety regulatory capacity.

The Chinese Academy of Sciences facility, one of the largest of its kind, scaled up robotic design-build-test infrastructure intended to speed the engineering of microorganisms for industrial and agricultural applications, part of China's broader push into engineering biology.

The Common Mechanism, designed to check gene synthesis orders against sequences of concern, gained further gene synthesis providers as users, including some in lower-income countries that had lacked access to commercial biosecurity screening software.

Grants to university-based automated design-build-test facilities aimed to translate the country's strength in synthetic biology research into commercial products faster, part of a strategy naming engineering biology one of a handful of technologies judged critical to future growth.

Baker's laboratory's tools for designing entirely new proteins not found in nature, recognised alongside related structure-prediction work by Demis Hassabis and John Jumper, marked synthetic biology's shift from redesigning existing organisms toward designing biological parts from scratch.

Governments and AI companies meeting in South Korea agreed voluntary commitments to test frontier models for the potential to assist in designing dangerous pathogens, extending AI safety governance into the overlap between generative design tools and biosecurity.

The trial targets Clostridioides difficile infection using an engineered living organism as the therapeutic. It marks the entry of engineered live biotherapeutics into human clinical testing.

Grants from state research foundations supported university laboratories working on engineered microorganisms for agricultural and industrial applications, part of a broader Latin American effort to build synthetic biology capacity beyond the traditional US, European and Chinese centres.

The network, which links automated biological engineering facilities to share standards and best practice, continued to grow beyond its original membership of wealthy-country institutions, reflecting the spread of biofoundry infrastructure to a wider set of countries.

Researchers led in part by Tianjin University worked toward finishing and consolidating a redesigned yeast genome built chromosome by chromosome, a project spanning US, UK, Chinese, Singaporean and Australian laboratories and a proof of concept for engineering complex organisms.

RNA-based systems act faster than DNA counterparts as they need no transcription, and are safer because they do not integrate into the host genome. These advances expanded applications in gene therapy, personalised medicine and vaccine development.

The embryo models were derived entirely from stem cells rather than fertilisation. The achievement raised acute ethical questions alongside its scientific significance.

An external ear was bioprinted to treat microtia. It was the first clinical success for patient-derived bioprinted tissue.

The AI model enabled prediction of structures for virtually all 200 million identified proteins and has since been used by more than two million people across 190 countries. Applications include understanding antibiotic resistance and designing plastic-degrading enzymes.

The xenobot was assembled from frog cells with its body plan designed by artificial intelligence. In 2021 xenobots were reported to self-replicate by gathering loose cells to form new ones.

The team reduced the natural 64 codons to 59 while still encoding 20 amino acids. It was a milestone in recoding whole genomes and producing organisms with genetics unlike anything in nature.

The work brought machine learning primitives into engineered living systems. It opened a route to adaptive rather than fixed genetic circuits.

The genome was generated entirely by computer, though no viable organism carrying it yet existed. It demonstrated that genome design could be fully computational.

The large-scale collaboration was followed by national synthetic cell organisations including FabriCell, MaxSynBio and BaSyC. European efforts were unified in 2019 as the SynCellEU initiative.

Boolean logic and arithmetic through DNA excision enabled complex engineered computation inside human cells. It advanced the prospect of programmable cell therapies.

The sector had spread well beyond its founding academic centres into a global commercial market. It marked the field's transition from laboratory science to industry.

The demonstration showed that genetic circuits could be compiled from specifications rather than hand-built. It moved synthetic biology closer to true engineering abstraction.

JCVI-syn3.0, built by systematically removing genes from a synthetic genome until only around 470 remained essential, offered a minimal biological chassis for engineers to build new functions onto without unnecessary genetic complexity.

The team produced the first living organism with an artificially expanded DNA code, using E. coli whose genome was replaced with an expanded-alphabet chromosome. It broke the four-letter constraint of natural genetics.

Friends of the Earth, the International Center for Technology Assessment and the ETC Group were among the signatories. The manifesto represented organised civil-society pressure for precautionary regulation of the field.

The Science paper repurposed a bacterial immune system into a programmable editing tool. It greatly simplified and expanded eukaryotic gene editing, transforming what synthetic biologists could attempt.

The US defence research agency funded development of automated tools for designing, building and testing engineered organisms faster and more cheaply, helping establish the biofoundry model that later spread to universities and companies worldwide.

Building on the mammalian logic evaluator, the team produced a proof-of-concept therapy using engineered cellular computation. It linked synthetic circuits directly to clinical ambitions.